IL25 and rheumatoid arthritis: It acts through the STAT3 and p38 MAPK/NF-κB inhibitor alpha pathways, inhibits osteoclast differentiation and related marker expression, suggesting that IL-25 is a potential therapeutic target for RA (Min et al., 2020).